Citi analyst Joanne Wuensch upgraded Silk Road Medical to Buy from Neutral with an unchanged price target of $50. Most medical technology companies met expectations in Q4, which bodes well for Q1, the analyst tells investors in a research note. The firm says the sector has historically "worked" in a "beat and raise environment" and has historically been "recession resistant."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical initiated with a Buy at B. Riley
- Silk Road Medical upgraded to Neutral from Sell at Citi
- Silk Road Medical reports Q4 EPS (34c), consensus (38c)
- Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook
- Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
